FIRMQUARRYResearch workspace

GOVERNMENT CONTRACT / PURCHASE ORDER

BISPECIFIC ANTIBODIES AGAINST CT-RCC HERV-E

Awarded to MYRIO THERAPEUTICS PTY LTD

PIID 75N92024P00043US · USAspendingResearch & Science
$51.8K
Data last updated Oct 22, 2026 · Source: USAspending
Transaction obligation$51,836sum disclosed on award record
Current contract valueNot reportednot interchangeable with obligation
Potential contract valueNot reportedincluding options if reported
Award dateFeb 1, 2024
Company legal name
MYRIO THERAPEUTICS PTY LTD
UEI / CAGE
ZNWKZF5TAEU2 / Not reported
Parent award
Not reported
Awarding agency
Department of Health and Human Services
Subagency
National Institutes of Health
Industry
Research & Science
NAICS
541715
PSC
Q301
Performance period
Not reported — Not reported
Recipient address
1/6-16 JOSEPH ST, BLACKBURN NORTH
Place of performance
Not reported
Source last modified
Nov 2, 2026

Description

BISPECIFIC ANTIBODIES AGAINST CT-RCC HERV-E

View federal source ↗

Derived from official transactions

Contract lifecycle

  1. Award announced

    BISPECIFIC ANTIBODIES AGAINST CT-RCC HERV-E

    US · usaspendingSource ↗

Point-in-time model

Contract change outlook

Predictive intelligenceInsufficient historyNo eligible point-in-time model has produced a prediction for this record.

Uncollapsed source history

Transactions and modifications

Action dateModificationAction typeExact obligationCurrent totalPotential totalDescriptionSource
Jan 18, 20240Not reported$51,836.00Not reportedNot reportedBISPECIFIC ANTIBODIES AGAINST CT-RCC HERV-EUSAspending ↗